comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 00:34:03 - browse：12

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Why you get paid to donate plasma but not blood

WSS

Readout LOUD podcast: possible new ALS drug, artificial wombs

ER docs worry over extreme heat as a 'mass casualty event'

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

More hospitals are billing patients as online messages surge

A look at other Americans who have crossed into North Korea over the years

Why are Kaiser Permanente staff considering a strike?

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

Microbiome research is starting to find links to chronic diseases

Wildfire smoke exposes gaps in outdoor worker protections

What we know about the American soldier detained in North Korea

How one medical school became remarkably diverse

What we know about the American soldier detained in North Korea

Medicare proposal to cover medical devices draws a mixed reaction

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

After affirmative action ruling, medical educators look to 'holistic review'

UK homeowners get some respite as inflation falls by more than anticipated to a 15

leisure time

Study: Hearing aids may slow cognitive decline in those at risk

A strong 6.5

Robert Kennedy Jr.'s presidential campaign attracts GOP

Senators: Long

Drug for rare kidney disease narrowly misses mark in clinical trial

More hospitals are billing patients as online messages surge

focus

focus

knowledge

leisure time